查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2135479

RNA-LNP療法市場：全球市場預測，2026-2032年

RNA-LNP Formulation Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，RNA-LNP 製劑市場將成長至 51.9 億美元，複合年成長率為 9.76%。

主要市場統計數據
基準年 2025 27億美元
預計年份：2026年 29.9億美元
預測年份 2032 51.9億美元
複合年成長率 (%) 9.76%

RNA-LNP 製備：概述

RNA-脂質奈米顆粒（RNA-LNP）製劑是一種專注於RNA有效載荷（包括傳訊RNA和其他核酸）封裝和運輸的藥物遞送技術。其發展得益於可電離脂質、輔助脂質、膽固醇、聚乙二醇-脂質組分、顆粒製造、分析表徵以及冷鍊和穩定性控制等方面的進步。此領域應用廣泛，涵蓋免疫接種和治療性疫苗、蛋白質替代療法、基因調控以及新興的體內基因療法。

平台成熟正在重塑 RNA-LNP 的開發。

目前，藥物研發的重點正從概念驗證（PoC）轉向可重複、可擴展且針對特定應用的製劑設計。研發人員更重視酬載的完整性、包封一致性、組織分佈、耐受性、儲存穩定性、可生產性。連續和微流體混合、製程分析技術、改進的脂質庫以及更嚴格的可比性策略，正在促進實驗室製劑開發與規範化生產之間的協調。同時，跨膜遞送仍是一項核心技術挑戰，推動著標靶化配體、生物可分解材料和器官選擇性顆粒結構的研究。

人工智慧加速藥物設計和控制。

人工智慧可以透過關聯分散資料集中的脂質結構、程式參數、顆粒特性、生物性能和安全性等觀測結果，影響RNA-LNP製劑的開發。機器學習模型可以輔助候選化合物的優先排序、實驗設計、異常檢測、製劑最佳化以及穩定性和組織分佈的預測。其實際價值取決於高品質、標準化的數據、透明的檢驗、實驗支援以及用於解決模型漂移和偏差的控制措施。短期內，其最大的貢獻可能是決策支持，減少低效率的迭代工作，而不是取代實驗室或監管機構的判斷。

區域趨勢：既有能力與新興基礎設施

北美地區擁有先進的生物技術研究、臨床開發能力、專業生產能力和監管經驗，而拉丁美洲則致力於加強轉化研究、本地生產能力以及以患者可及性為導向的夥伴關係。歐洲受益於協調的科學網路和完善的製藥基礎設施，但其生產和監管體係因國家而異。中東地區正在投資生命科學能力和技術夥伴關係，而非洲則優先發展研究能力、提升醫療韌性並促進技術轉移。亞太地區在生物製造方面擁有豐富的專業知識，不斷拓展研究項目，並擁有多元化的法規環境。澳洲、中國、印度、日本和韓國在研究、生產或臨床應用方面各具優勢。

多邊組織塑造標準、資金籌措和供應韌性。

東協合作能夠促進區域協調、技術轉讓，並確保更穩定地獲得先進生物製造技術。金磚國家成員國在科學、產業和公共部門領域擁有強大的實力，但不同監管體系之間的協調仍然至關重要。歐盟為聯合研究、監管協調和供應鏈韌性提供了框架。七國集團在研發、資金籌措、製造和衛生政策方面貢獻了關鍵能力。海灣合作理事會成員國正在建立專門的生命科學基礎設施和夥伴關係，而北約成員國更廣泛的創新和韌性優先事項則有助於在不損害私營監管要求的前提下，為安全生物醫學供應鏈和兩用物項製造做好準備。

每個國家的能力都反映了其不同的研發和製造重點。

美國和加拿大擁有強大的基礎研究、臨床研究和生物製程系統。巴西和墨西哥正在擴大在該地區的生產製造、研究和醫療保健能力。中國在生命科學領域投入巨資，並持續提升製劑和生產技術水準；印度則憑藉其龐大的製藥生產規模和廣泛的科研人才隊伍做出貢獻。日本、韓國和澳洲支持先進的研究、品管系統和專業的生物製造。在歐洲，法國、德國、義大利、西班牙和英國在轉化科學、藥品生產、監管和臨床網路方面發揮互補優勢。俄羅斯保持其科學研究和產業實力，但技術取得、合作條件和供應鏈的限制可能會影響其發展速度。

優先考慮穩健、有針對性且易於生產的配方策略。

產業領導者應基於明確的臨床應用案例建構製劑組合，而非僅僅追求效力最佳化，並儘早進行耐受性、生物分佈、穩定性及可擴展生產的篩檢。他們還應建立整合的數據標準，將原料特性、製程條件、關鍵品質屬性和生物學結果關聯起來；僅在檢驗的實驗流程中應用人工智慧；並開發正交分析方法，用於分析粒徑、包封率、活性成分完整性、雜質和釋放行為。與本地製造商、監管機構、臨床中心和學術機構建立合作關係，將有助於提高技術轉移效率和韌性。最後，企業應從研發初期就規劃好儲存、分銷、原料合格、基於知識產權的商業自由實施以及整個生命週期的可比性。

調查方法：基於證據的RNA-LNP製劑評價

本執行摘要對與RNA-LNP製劑相關的既有科學、生產、監管和醫療保健系統因素進行了定性整合。評估系統地整理了製劑材料、生產流程、分析控制、遞送生物學、人工智慧應用、區域生態系統、跨國集團和國家能力等方面的證據。分析結果是基於已記錄的技術特性和公開可觀察的基礎設施模式。本摘要未使用任何市場規模估算或預測、市場佔有率、預測或公司特定聲明。投資和開發決策應參考最新的原始文獻、監管出版刊物、臨床檢驗記錄和已驗證的生產數據，以補充本摘要的結論。

RNA-LNP 的執行品質將決定其下一步發展方向。

RNA-LNP製劑的研發正透過整合脂質化學、精密製造、分析、計算設計和轉化醫學而不斷推進。持續進展不僅取決於有效載荷活性的提升，還取決於對遞送選擇性、耐受性、穩定性、工藝可重複性和公平生產等挑戰的應對。那些將製劑科學與嚴格的品質系統、檢驗的數據管理方法、區域夥伴關係以及切合實際的臨床需求相結合的機構，將更有能力將前景廣闊的RNA概念轉化為可靠的療法和疫苗。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 RNA-LNP療法市場：依產品類型分類

  • miRNA
    • 雙鏈miRNA
    • 單鏈miRNA
  • mRNA
    • 未擴增的mRNA
    • 自擴增mRNA
  • pDNA
    • 環狀DNA
    • 線性DNA
  • siRNA
    • 修飾的siRNA
    • 標準siRNA

第8章 RNA-LNP製劑市場：依脂質組成分類

  • 膽固醇
    • 天然膽固醇
    • 合成膽固醇
  • 可電離脂質
    • ALC-0315
    • DLin-MC3-DMA
    • SM-102
  • PEG脂質
    • DMG-PEG
    • DSPE-PEG
  • 磷脂
    • DOPE
    • DSPC

第9章 RNA-LNP療法市場：按收費

  • 陰離子
    • DOPA
    • DOPS
  • 陽離子性質
    • DOTAP
    • DOTMA
  • 中性的

第10章：RNA-LNP治療市場：依應用領域分類

  • 基因編輯
    • CRISPR 基礎
    • TALEN 貝斯
    • ZFN 基體
  • 治療
    • 心血管治療
    • 癌症治療藥物
    • 罕見疾病的治療
  • 疫苗
    • 感染疾病
    • 癌症疫苗

第11章 RNA-LNP療法市場：以最終用戶分類

  • 學術研究機構
  • 合約研發生產組織（CDMO）
    • 一級
    • 二級
  • 製藥和生物技術公司

第12章 RNA-LNP療法市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 RNA-LNP療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 RNA-LNP療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Alnylam Pharmaceuticals, Inc.
  • Avanti Polar Lipids, Inc.
  • BIOVECTRA Inc.
  • CordenPharma International
  • Curapath
  • Curia Global, Inc.
  • Emergent BioSolutions Inc.
  • EUROAPI SA
  • Evonik Industries AG
  • Exelead
  • Genevant Sciences, Inc.
  • Lipoid GmbH
  • Merck KGaA
  • Nippon Fine Chemical Co., Ltd.
  • Precision NanoSystems Inc.

第17章 主要專家

Product Code: MRR-961F26FD646A

The RNA-LNP Formulation Market is projected to grow by USD 5.19 billion at a CAGR of 9.76% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.70 billion
Estimated Year [2026] USD 2.99 billion
Forecast Year [2032] USD 5.19 billion
CAGR (%) 9.76%

RNA-LNP Formulation: Executive Overview

RNA-lipid nanoparticle (RNA-LNP) formulation is a drug-delivery field focused on encapsulating and transporting RNA payloads, including messenger RNA and other nucleic-acid modalities. Its development is shaped by advances in ionizable lipids, helper lipids, cholesterol, polyethylene glycol-lipid components, particle manufacturing, analytical characterization, and cold-chain or stability management. The field serves applications spanning preventive immunization, therapeutic vaccines, protein replacement, gene regulation, and emerging in vivo genetic medicines.

Platform Maturity Is Reshaping RNA-LNP Development

The landscape is shifting from proof-of-concept delivery toward reproducible, scalable, and application-specific formulation design. Developers are placing greater emphasis on payload integrity, encapsulation consistency, tissue distribution, tolerability, storage stability, and manufacturability. Continuous and microfluidic mixing, process analytical technologies, improved lipid libraries, and more rigorous comparability strategies are helping connect laboratory formulation work with regulated production. At the same time, delivery beyond the liver remains a central technical challenge, encouraging research into targeting ligands, biodegradable materials, and organ-selective particle architectures.

Artificial Intelligence Accelerates Formulation Design and Control

Artificial intelligence can influence RNA-LNP formulation by linking lipid structure, process parameters, particle attributes, biological performance, and safety observations across fragmented datasets. Machine-learning models may support candidate prioritization, design-of-experiments planning, anomaly detection, formulation optimization, and prediction of stability or tissue distribution. Its practical value depends on high-quality standardized data, transparent validation, experimental confirmation, and controls that address model drift and bias. The strongest near-term contribution is likely to be decision support that reduces inefficient iteration rather than replacement of laboratory and regulatory judgment.

Regional Dynamics Span Established Capability and Emerging Infrastructure

North America combines advanced biotechnology research, clinical development capacity, specialized manufacturing, and regulatory experience, while Latin America is strengthening translational research, local production capabilities, and access-oriented partnerships. Europe benefits from coordinated scientific networks and sophisticated pharmaceutical infrastructure, with variation among national manufacturing and regulatory ecosystems. The Middle East is investing in life-science capability and technology partnerships, and Africa is prioritizing research capacity, healthcare resilience, and technology transfer. Asia-Pacific brings substantial biomanufacturing depth, expanding research programs, and diverse regulatory environments; Australia, China, India, Japan, and South Korea each contribute distinct strengths in research, manufacturing, or clinical translation.

Multilateral Groups Shape Standards, Funding, and Supply Resilience

ASEAN cooperation can support regional alignment, technology transfer, and more consistent access to advanced biomanufacturing. BRICS members bring significant scientific, industrial, and public-sector capacity, but coordination across differing regulatory systems remains important. The European Union provides a framework for collaborative research, regulatory convergence, and supply-chain resilience. G7 economies contribute major research, financing, manufacturing, and health-policy capabilities. GCC countries are developing specialized life-science infrastructure and partnerships, while NATO members' broader innovation and resilience priorities can support secure biomedical supply chains and dual-use manufacturing preparedness without replacing civilian regulatory requirements.

Country Capabilities Reflect Distinct Research and Manufacturing Priorities

The United States and Canada offer strong discovery, clinical, and bioprocessing ecosystems. Brazil and Mexico are expanding regional manufacturing, research, and healthcare capabilities. China combines substantial life-science investment with growing formulation and production expertise, while India contributes pharmaceutical manufacturing scale and a broad scientific workforce. Japan, South Korea, and Australia support advanced research, quality systems, and specialized biomanufacturing. In Europe, France, Germany, Italy, Spain, and the United Kingdom contribute complementary strengths in translational science, pharmaceutical production, regulation, and clinical networks. Russia retains scientific and industrial capabilities, although access to technologies, collaboration conditions, and supply-chain constraints can affect development pathways.

Prioritize Robust, Targeted, and Manufacturable Formulation Strategies

Industry leaders should build formulation portfolios around clearly defined clinical use cases, with early screening for tolerability, biodistribution, stability, and scalable production rather than optimizing potency alone. They should establish integrated data standards linking material identity, process conditions, critical quality attributes, and biological outcomes; use artificial intelligence only within validated experimental workflows; and develop orthogonal analytical methods for particle size, encapsulation, payload integrity, impurities, and release behavior. Partnerships with regional manufacturers, regulators, clinical centers, and academic groups can improve technology transfer and resilience. Finally, organizations should plan for storage, distribution, raw-material qualification, intellectual-property freedom to operate, and lifecycle comparability from the beginning of development.

Methodology: Evidence-Based Assessment of RNA-LNP Formulation

This executive summary uses a qualitative synthesis of established scientific, manufacturing, regulatory, and healthcare-system considerations relevant to RNA-LNP formulation. The assessment organizes evidence across formulation materials, production processes, analytical control, delivery biology, artificial-intelligence applications, regional ecosystems, multinational groupings, and national capabilities. Insights are framed around documented technology characteristics and publicly observable infrastructure patterns. No market estimates, market shares, forecasts, or company-specific claims are used; conclusions should be supplemented with current primary literature, regulatory publications, clinical-trial records, and validated manufacturing data for investment or development decisions.

Execution Quality Will Determine the Next Phase of RNA-LNP Progress

RNA-LNP formulation is advancing through the convergence of lipid chemistry, precision manufacturing, analytics, computational design, and translational medicine. Sustainable progress will depend on solving delivery selectivity, tolerability, stability, process reproducibility, and equitable production-not simply increasing payload activity. Organizations that connect formulation science with rigorous quality systems, validated data practices, regional partnerships, and realistic clinical requirements will be better positioned to translate promising RNA concepts into reliable therapies and vaccines.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. RNA-LNP Formulation Market, by Product Type

  • 7.1. Introduction
  • 7.2. miRNA
    • 7.2.1. Double Strand miRNA
    • 7.2.2. Single Strand miRNA
  • 7.3. mRNA
    • 7.3.1. Non Amplifying mRNA
    • 7.3.2. Self Amplifying mRNA
  • 7.4. pDNA
    • 7.4.1. Circular DNA
    • 7.4.2. Linear DNA
  • 7.5. siRNA
    • 7.5.1. Modified siRNA
    • 7.5.2. Standard siRNA

8. RNA-LNP Formulation Market, by Lipid Composition

  • 8.1. Introduction
  • 8.2. Cholesterol
    • 8.2.1. Natural Cholesterol
    • 8.2.2. Synthetic Cholesterol
  • 8.3. Ionizable Lipid
    • 8.3.1. ALC-0315
    • 8.3.2. DLin-MC3-DMA
    • 8.3.3. SM-102
  • 8.4. PEG Lipids
    • 8.4.1. DMG-PEG
    • 8.4.2. DSPE-PEG
  • 8.5. Phospholipid
    • 8.5.1. DOPE
    • 8.5.2. DSPC

9. RNA-LNP Formulation Market, by Charge

  • 9.1. Introduction
  • 9.2. Anionic
    • 9.2.1. DOPA
    • 9.2.2. DOPS
  • 9.3. Cationic
    • 9.3.1. DOTAP
    • 9.3.2. DOTMA
  • 9.4. Neutral

10. RNA-LNP Formulation Market, by Application

  • 10.1. Introduction
  • 10.2. Gene Editing
    • 10.2.1. CRISPR Based
    • 10.2.2. TALEN Based
    • 10.2.3. ZFN Based
  • 10.3. Therapeutics
    • 10.3.1. Cardiovascular Therapies
    • 10.3.2. Oncology Therapeutics
    • 10.3.3. Rare Disease Therapeutics
  • 10.4. Vaccines
    • 10.4.1. Infectious Disease
    • 10.4.2. Oncology Vaccines

11. RNA-LNP Formulation Market, by End User

  • 11.1. Introduction
  • 11.2. Academic And Research Institutes
  • 11.3. Contract Development And Manufacturing Organizations
    • 11.3.1. Tier One
    • 11.3.2. Tier Two
  • 11.4. Pharmaceutical And Biotech Companies

12. RNA-LNP Formulation Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. RNA-LNP Formulation Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. RNA-LNP Formulation Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Alnylam Pharmaceuticals, Inc.
  • 16.2. Avanti Polar Lipids, Inc.
  • 16.3. BIOVECTRA Inc.
  • 16.4. CordenPharma International
  • 16.5. Curapath
  • 16.6. Curia Global, Inc.
  • 16.7. Emergent BioSolutions Inc.
  • 16.8. EUROAPI S.A.
  • 16.9. Evonik Industries AG
  • 16.10. Exelead
  • 16.11. Genevant Sciences, Inc.
  • 16.12. Lipoid GmbH
  • 16.13. Merck KGaA
  • 16.14. Nippon Fine Chemical Co., Ltd.
  • 16.15. Precision NanoSystems Inc.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global RNA-LNP Formulation Market, Years Considered for the Study
  • FIGURE 2. Global RNA-LNP Formulation Market, Research Design
  • FIGURE 3. Global RNA-LNP Formulation Market, Research Framework
  • FIGURE 4. Global RNA-LNP Formulation Market, Data Triangulation
  • FIGURE 5. Global RNA-LNP Formulation Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global RNA-LNP Formulation Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global RNA-LNP Formulation Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global RNA-LNP Formulation Market Size, by Lipid Composition, 2025 vs 2032 (%)
  • FIGURE 9. Global RNA-LNP Formulation Market Size, by Lipid Composition, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global RNA-LNP Formulation Market Size, by Charge, 2025 vs 2032 (%)
  • FIGURE 11. Global RNA-LNP Formulation Market Size, by Charge, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global RNA-LNP Formulation Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 13. Global RNA-LNP Formulation Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global RNA-LNP Formulation Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global RNA-LNP Formulation Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global RNA-LNP Formulation Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global RNA-LNP Formulation Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global RNA-LNP Formulation Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global RNA-LNP Formulation Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global RNA-LNP Formulation Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global RNA-LNP Formulation Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global RNA-LNP Formulation Market Segmentation & Coverage
  • TABLE 2. Global RNA-LNP Formulation Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global RNA-LNP Formulation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global miRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global miRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global miRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Double Strand miRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Double Strand miRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Double Strand miRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Single Strand miRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Single Strand miRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Single Strand miRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global mRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global mRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global mRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Non Amplifying mRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Non Amplifying mRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Non Amplifying mRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Self Amplifying mRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Self Amplifying mRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Self Amplifying mRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global pDNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global pDNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global pDNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Circular DNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Circular DNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Circular DNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Linear DNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Linear DNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Linear DNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global siRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global siRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global siRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Modified siRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Modified siRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Modified siRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Standard siRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Standard siRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Standard siRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global RNA-LNP Formulation Market Size, by Lipid Composition, 2017-2032 (USD Million)
  • TABLE 41. Global Cholesterol Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Cholesterol Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Cholesterol Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Natural Cholesterol Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Natural Cholesterol Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Natural Cholesterol Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Synthetic Cholesterol Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Synthetic Cholesterol Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Synthetic Cholesterol Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Ionizable Lipid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Ionizable Lipid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Ionizable Lipid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global ALC-0315 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global ALC-0315 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global ALC-0315 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global DLin-MC3-DMA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global DLin-MC3-DMA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global DLin-MC3-DMA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global SM-102 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global SM-102 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global SM-102 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global PEG Lipids Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Global PEG Lipids Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 64. Global PEG Lipids Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 65. Global DMG-PEG Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global DMG-PEG Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global DMG-PEG Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global DSPE-PEG Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Global DSPE-PEG Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 70. Global DSPE-PEG Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 71. Global Phospholipid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Phospholipid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Phospholipid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global DOPE Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Global DOPE Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 76. Global DOPE Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 77. Global DSPC Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Global DSPC Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. Global DSPC Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 80. Global RNA-LNP Formulation Market Size, by Charge, 2017-2032 (USD Million)
  • TABLE 81. Global Anionic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Anionic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Anionic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global DOPA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 85. Global DOPA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. Global DOPA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 87. Global DOPS Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Global DOPS Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 89. Global DOPS Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 90. Global Cationic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 91. Global Cationic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. Global Cationic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 93. Global DOTAP Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Global DOTAP Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 95. Global DOTAP Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 96. Global DOTMA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 97. Global DOTMA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 98. Global DOTMA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 99. Global Neutral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 100. Global Neutral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 101. Global Neutral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 102. Global RNA-LNP Formulation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 103. Global Gene Editing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 104. Global Gene Editing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 105. Global Gene Editing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 106. Global CRISPR Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 107. Global CRISPR Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 108. Global CRISPR Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 109. Global TALEN Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 110. Global TALEN Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 111. Global TALEN Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 112. Global ZFN Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 113. Global ZFN Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 114. Global ZFN Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 115. Global Therapeutics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 116. Global Therapeutics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 117. Global Therapeutics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 118. Global Cardiovascular Therapies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 119. Global Cardiovascular Therapies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 120. Global Cardiovascular Therapies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 121. Global Oncology Therapeutics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 122. Global Oncology Therapeutics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 123. Global Oncology Therapeutics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 124. Global Rare Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 125. Global Rare Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 126. Global Rare Disease Therapeutics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 127. Global Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 128. Global Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 129. Global Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 130. Global Infectious Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 131. Global Infectious Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 132. Global Infectious Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 133. Global Oncology Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 134. Global Oncology Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 135. Global Oncology Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 136. Global RNA-LNP Formulation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 137. Global Academic And Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 138. Global Academic And Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 139. Global Academic And Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 140. Global Contract Development And Manufacturing Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 141. Global Contract Development And Manufacturing Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 142. Global Contract Development And Manufacturing Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 143. Global Tier One Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 144. Global Tier One Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 145. Global Tier One Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 146. Global Tier Two Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 147. Global Tier Two Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 148. Global Tier Two Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 149. Global Pharmaceutical And Biotech Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 150. Global Pharmaceutical And Biotech Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 151. Global Pharmaceutical And Biotech Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 152. Global RNA-LNP Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 153. Asia-Pacific RNA-LNP Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 154. Asia-Pacific RNA-LNP Formulation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 155. Asia-Pacific RNA-LNP Formulation Market Size, by miRNA, 2017-2032 (USD Million)
  • TABLE 156. Asia-Pacific RNA-LNP Formulation Market Size, by mRNA, 2017-2032 (USD Million)
  • TABLE 157. Asia-Pacific RNA-LNP Formulation Market Size, by pDNA, 2017-2032 (USD Million)
  • TABLE 158. Asia-Pacific RNA-LNP Formulation Market Size, by siRNA, 2017-2032 (USD Million)
  • TABLE 159. Asia-Pacific RNA-LNP Formulation Market Size, by Lipid Composition, 2017-2032 (USD Million)
  • TABLE 160. Asia-Pacific RNA-LNP Formulation Market Size, by Cholesterol, 2017-2032 (USD Million)
  • TABLE 161. Asia-Pacific RNA-LNP Formulation Market Size, by Ionizable Lipid, 2017-2032 (USD Million)
  • TABLE 162. Asia-Pacific RNA-LNP Formulation Market Size, by PEG Lipids, 2017-2032 (USD Million)
  • TABLE 163. Asia-Pacific RNA-LNP Formulation Market Size, by Phospholipid, 2017-2032 (USD Million)
  • TABLE 164. Asia-Pacific RNA-LNP Formulation Market Size, by Charge, 2017-2032 (USD Million)
  • TABLE 165. Asia-Pacific RNA-LNP Formulation Market Size, by Anionic, 2017-2032 (USD Million)
  • TABLE 166. Asia-Pacific RNA-LNP Formulation Market Size, by Cationic, 2017-2032 (USD Million)
  • TABLE 167. Asia-Pacific RNA-LNP Formulation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 168. Asia-Pacific RNA-LNP Formulation Market Size, by Gene Editing, 2017-2032 (USD Million)
  • TABLE 169. Asia-Pacific RNA-LNP Formulation Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 170. Asia-Pacific RNA-LNP Formulation Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 171. Asia-Pacific RNA-LNP Formulation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 172. Asia-Pacific RNA-LNP Formulation Market Size, by Contract Development And Manufacturing Organizations, 2017-2032 (USD Million)
  • TABLE 173. North America RNA-LNP Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 174. North America RNA-LNP Formulation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 175. North America RNA-LNP Formulation Market Size, by miRNA, 2017-2032 (USD Million)
  • TABLE 176. North America RNA-LNP Formulation Market Size, by mRNA, 2017-2032 (USD Million)
  • TABLE 177. North America RNA-LNP Formulation Market Size, by pDNA, 2017-2032 (USD Million)
  • TABLE 178. North America RNA-LNP Formulation Market Size, by siRNA, 2017-2032 (USD Million)
  • TABLE 179. North America RNA-LNP Formulation Market Size, by Lipid Composition, 2017-2032 (USD Million)
  • TABLE 180. North America RNA-LNP Formulation Market Size, by Cholesterol, 2017-2032 (USD Million)
  • TABLE 181. North America RNA-LNP Formulation Market Size, by Ionizable Lipid, 2017-2032 (USD Million)
  • TABLE 182. North America RNA-LNP Formulation Market Size, by PEG Lipids, 2017-2032 (USD Million)
  • TABLE 183. North America RNA-LNP Formulation Market Size, by Phospholipid, 2017-2032 (USD Million)
  • TABLE 184. North America RNA-LNP Formulation Market Size, by Charge, 2017-2032 (USD Million)
  • TABLE 185. North America RNA-LNP Formulation Market Size, by Anionic, 2017-2032 (USD Million)
  • TABLE 186. North America RNA-LNP Formulation Market Size, by Cationic, 2017-2032 (USD Million)
  • TABLE 187. North America RNA-LNP Formulation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 188. North America RNA-LNP Formulation Market Size, by Gene Editing, 2017-2032 (USD Million)
  • TABLE 189. North America RNA-LNP Formulation Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 190. North America RNA-LNP Formulation Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 191. North America RNA-LNP Formulation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 192. North America RNA-LNP Formulation Market Size, by Contract Development And Manufacturing Organizations, 2017-2032 (USD Million)
  • TABLE 193. Latin America RNA-LNP Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 194. Latin America RNA-LNP Formulation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 195. Latin America RNA-LNP Formulation Market Size, by miRNA, 2017-2032 (USD Million)
  • TABLE 196. Latin America RNA-LNP Formulation Market Size, by mRNA, 2017-2032 (USD Million)
  • TABLE 197. Latin America RNA-LNP Formulation Market Size, by pDNA, 2017-2032 (USD Million)
  • TABLE 198. Latin America RNA-LNP Formulation Market Size, by siRNA, 2017-2032 (USD Million)
  • TABLE 199. Latin America RNA-LNP Formulation Market Size, by Lipid Composition, 2017-2032 (USD Million)
  • TABLE 200. Latin America RNA-LNP Formulation Market Size, by Cholesterol, 2017-2032 (USD Million)
  • TABLE 201. Latin America RNA-LNP Formulation Market Size, by Ionizable Lipid, 2017-2032 (USD Million)
  • TABLE 202. Latin America RNA-LNP Formulation Market Size, by PEG Lipids, 2017-2032 (USD Million)
  • TABLE 203. Latin America RNA-LNP Formulation Market Size, by Phospholipid, 2017-2032 (USD Million)
  • TABLE 204. Latin America RNA-LNP Formulation Market Size, by Charge, 2017-2032 (USD Million)
  • TABLE 205. Latin America RNA-LNP Formulation Market Size, by Anionic, 2017-2032 (USD Million)
  • TABLE 206. Latin America RNA-LNP Formulation Market Size, by Cationic, 2017-2032 (USD Million)
  • TABLE 207. Latin America RNA-LNP Formulation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 208. Latin America RNA-LNP Formulation Market Size, by Gene Editing, 2017-2032 (USD Million)
  • TABLE 209. Latin America RNA-LNP Formulation Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 210. Latin America RNA-LNP Formulation Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 211. Latin America RNA-LNP Formulation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 212. Latin America RNA-LNP Formulation Market Size, by Contract Development And Manufacturing Organizations, 2017-2032 (USD Million)
  • TABLE 213. Europe RNA-LNP Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 214. Europe RNA-LNP Formulation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 215. Europe RNA-LNP Formulation Market Size, by miRNA, 2017-2032 (USD Million)
  • TABLE 216. Europe RNA-LNP Formulation Market Size, by mRNA, 2017-2032 (USD Million)
  • TABLE 217. Europe RNA-LNP Formulation Market Size, by pDNA, 2017-2032 (USD Million)
  • TABLE 218. Europe RNA-LNP Formulation Market Size, by siRNA, 2017-2032 (USD Million)
  • TABLE 219. Europe RNA-LNP Formulation Market Size, by Lipid Composition, 2017-2032 (USD Million)
  • TABLE 220. Europe RNA-LNP Formulation Market Size, by Cholesterol, 2017-2032 (USD Million)
  • TABLE 221. Europe RNA-LNP Formulation Market Size, by Ionizable Lipid, 2017-2032 (USD Million)
  • TABLE 222. Europe RNA-LNP Formulation Market Size, by PEG Lipids, 2017-2032 (USD Million)
  • TABLE 223. Europe RNA-LNP Formulation Market Size, by Phospholipid, 2017-2032 (USD Million)
  • TABLE 224. Europe RNA-LNP Formulation Market Size, by Charge, 2017-2032 (USD Million)
  • TABLE 225. Europe RNA-LNP Formulation Market Size, by Anionic, 2017-2032 (USD Million)
  • TABLE 226. Europe RNA-LNP Formulation Market Size, by Cationic, 2017-2032 (USD Million)
  • TABLE 227. Europe RNA-LNP Formulation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 228. Europe RNA-LNP Formulation Market Size, by Gene Editing, 2017-2032 (USD Million)
  • TABLE 229. Europe RNA-LNP Formulation Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 230. Europe RNA-LNP Formulation Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 231. Europe RNA-LNP Formulation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 232. Europe RNA-LNP Formulation Market Size, by Contract Development And Manufacturing Organizations, 2017-2032 (USD Million)
  • TABLE 233. Middle East RNA-LNP Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 234. Middle East RNA-LNP Formulation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 235. Middle East RNA-LNP Formulation Market Size, by miRNA, 2017-2032 (USD Million)
  • TABLE 236. Middle East RNA-LNP Formulation Market Size, by mRNA, 2017-2032 (USD Million)
  • TABLE 237. Middle East RNA-LNP Formulation Market Size, by pDNA, 2017-2032 (USD Million)
  • TABLE 238. Middle East RNA-LNP Formulation Market Size, by siRNA, 2017-2032 (USD Million)
  • TABLE 239. Middle East RNA-LNP Formulation Market Size, by Lipid Composition, 2017-2032 (USD Million)
  • TABLE 240. Middle East RNA-LNP Formulation Market Size, by Cholesterol, 2017-2032 (USD Million)
  • TABLE 241. Middle East RNA-LNP Formulation Market Size, by Ionizable Lipid, 2017-2032 (USD Million)
  • TABLE 242. Middle East RNA-LNP Formulation Market Size, by PEG Lipids, 2017-2032 (USD Million)
  • TABLE 243. Middle East RNA-LNP Formulation Market Size, by Phospholipid, 2017-2032 (USD Million)
  • TABLE 244. Middle East RNA-LNP Formulation Market Size, by Charge, 2017-2032 (USD Million)
  • TABLE 245. Middle East RNA-LNP Formulation Market Size, by Anionic, 2017-2032 (USD Million)
  • TABLE 246. Middle East RNA-LNP Formulation Market Size, by Cationic, 2017-2032 (USD Million)
  • TABLE 247. Middle East RNA-LNP Formulation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 248. Middle East RNA-LNP Formulation Market Size, by Gene Editing, 2017-2032 (USD Million)
  • TABLE 249. Middle East RNA-LNP Formulation Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 250. Middle East RNA-LNP Formulation Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 251. Middle East RNA-LNP Formulation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 252. Middle East RNA-LNP Formulation Market Size, by Contract Development And Manufacturing Organizations, 2017-2032 (USD Million)
  • TABLE 253. Africa RNA-LNP Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 254. Africa RNA-LNP Formulation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 255. Africa RNA-LNP Formulation Market Size, by miRNA, 2017-2032 (USD Million)
  • TABLE 256. Africa RNA-LNP Formulation Market Size, by mRNA, 2017-2032 (USD Million)
  • TABLE 257. Africa RNA-LNP Formulation Market Size, by pDNA, 2017-2032 (USD Million)
  • TABLE 258. Africa RNA-LNP Formulation Market Size, by siRNA, 2017-2032 (USD Million)
  • TABLE 259. Africa RNA-LNP Formulation Market Size, by Lipid Composition, 2017-2032 (USD Million)
  • TABLE 260. Africa RNA-LNP Formulation Market Size, by Cholesterol, 2017-2032 (USD Million)
  • TABLE 261. Africa RNA-LNP Formulation Market Size, by Ionizable Lipid, 2017-2032 (USD Million)
  • TABLE 262. Africa RNA-LNP Formulation Market Size, by PEG Lipids, 2017-2032 (USD Million)
  • TABLE 263. Africa RNA-LNP Formulation Market Size, by Phospholipid, 2017-2032 (USD Million)
  • TABLE 264. Africa RNA-LNP Formulation Market Size, by Charge, 2017-2032 (USD Million)
  • TABLE 265. Africa RNA-LNP Formulation Market Size, by Anionic, 2017-2032 (USD Million)
  • TABLE 266. Africa RNA-LNP Formulation Market Size, by Cationic, 2017-2032 (USD Million)
  • TABLE 267. Africa RNA-LNP Formulation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 268. Africa RNA-LNP Formulation Market Size, by Gene Editing, 2017-2032 (USD Million)
  • TABLE 269. Africa RNA-LNP Formulation Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 270. Africa RNA-LNP Formulation Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 271. Africa RNA-LNP Formulation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 272. Africa RNA-LNP Formulation Market Size, by Contract Development And Manufacturing Organizations, 2017-2032 (USD Million)
  • TABLE 273. Global RNA-LNP Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 274. ASEAN RNA-LNP Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 275. ASEAN RNA-LNP Formulation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 276. ASEAN RNA-LNP Formulation Market Size, by miRNA, 2017-2032 (USD Million)
  • TABLE 277. ASEAN RNA-LNP Formulation Market Size, by mRNA, 2017-2032 (USD Million)
  • TABLE 278. ASEAN RNA-LNP Formulation Market Size, by pDNA, 2017-2032 (USD Million)
  • TABLE 279. ASEAN RNA-LNP Formulation Market Size, by siRNA, 2017-2032 (USD Million)
  • TABLE 280. ASEAN RNA-LNP Formulation Market Size, by Lipid Composition, 2017-2032 (USD Million)
  • TABLE 281. ASEAN RNA-LNP Formulation Market Size, by Cholesterol, 2017-2032 (USD Million)
  • TABLE 282. ASEAN RNA-LNP Formulation Market Size, by Ionizable Lipid, 2017-2032 (USD Million)
  • TABLE 283. ASEAN RNA-LNP Formulation Market Size, by PEG Lipids, 2017-2032 (USD Million)
  • TABLE 284. ASEAN RNA-LNP Formulation Market Size, by Phospholipid, 2017-2032 (USD Million)
  • TABLE 285. ASEAN RNA-LNP Formulation Market Size, by Charge, 2017-2032 (USD Million)
  • TABLE 286. ASEAN RNA-LNP Formulation Market Size, by Anionic, 2017-2032 (USD Million)
  • TABLE 287. ASEAN RNA-LNP Formulation Market Size, by Cationic, 2017-2032 (USD Million)
  • TABLE 288. ASEAN RNA-LNP Formulation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 289. ASEAN RNA-LNP Formulation Market Size, by Gene Editing, 2017-2032 (USD Million)
  • TABLE 290. ASEAN RNA-LNP Formulation Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 291. ASEAN RNA-LNP Formulation Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 292. ASEAN RNA-LNP Formulation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 293. ASEAN RNA-LNP Formulation Market Size, by Contract Development And Manufacturing Organizations, 2017-2032 (USD Million)
  • TABLE 294. GCC RNA-LNP Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 295. GCC RNA-LNP Formulation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 296. GCC RNA-LNP Formulation Market Size, by miRNA, 2017-2032 (USD Million)
  • TABLE 297. GCC RNA-LNP Formulation Market Size, by mRNA, 2017-2032 (USD Million)
  • TABLE 298. GCC RNA-LNP Formulation Market Size, by pDNA, 2017-2032 (USD Million)
  • TABLE 299. GCC RNA-LNP Formulation Market Size, by siRNA, 2017-2032 (USD Million)
  • TABLE 300. GCC RNA-LNP Formulation Market Size, by Lipid Composition, 2017-2032 (USD Million)
  • TABLE 301. GCC RNA-LNP Formulation Market Size, by Cholesterol, 2017-2032 (USD Million)
  • TABLE 302. GCC RNA-LNP Formulation Market Size, by Ionizable Lipid, 2017-2032 (USD Million)
  • TABLE 303. GCC RNA-LNP Formulation Market Size, by PEG Lipids, 2017-2032 (USD Million)
  • TABLE 304. GCC RNA-LNP Formulation Market Size, by Phospholipid, 2017-2032 (USD Million)
  • TABLE 305. GCC RNA-LNP Formulation Market Size, by Charge, 2017-2032 (USD Million)
  • TABLE 306. GCC RNA-LNP Formulation Market Size, by Anionic, 2017-2032 (USD Million)
  • TABLE 307. GCC RNA-LNP Formulation Market Size, by Cationic, 2017-2032 (USD Million)
  • TABLE 308. GCC RNA-LNP Formulation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 309. GCC RNA-LNP Formulation Market Size, by Gene Editing, 2017-2032 (USD Million)
  • TABLE 310. GCC RNA-LNP Formulation Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 311. GCC RNA-LNP Formulation Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 312. GCC RNA-LNP Formulation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 313. GCC RNA-LNP Formulation Market Size, by Contract Development And Manufacturing Organizations, 2017-2032 (USD Million)
  • TABLE 314. European Union RNA-LNP Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 315. European Union RNA-LNP Formulation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 316. European Union RNA-LNP Formulation Market Size, by miRNA, 2017-2032 (USD Million)
  • TABLE 317. European Union RNA-LNP Formulation Market Size, by mRNA, 2017-2032 (USD Million)
  • TABLE 318. European Union RNA-LNP Formulation Market Size, by pDNA, 2017-2032 (USD Million)
  • TABLE 319. European Union RNA-LNP Formulation Market Size, by siRNA, 2017-2032 (USD Million)
  • TABLE 320. European Union RNA-LNP Formulation Market Size, by Lipid Composition, 2017-2032 (USD Million)
  • TABLE 321. European Union RNA-LNP Formulation Market Size, by Cholesterol, 2017-2032 (USD Million)
  • TABLE 322. European Union RNA-LNP Formulation Market Size, by Ionizable Lipid, 2017-2032 (USD Million)
  • TABLE 323. European Union RNA-LNP Formulation Market Size, by PEG Lipids, 2017-2032 (USD Million)
  • TABLE 324. European Union RNA-LNP Formulation Market Size, by Phospholipid, 2017-2032 (USD Million)
  • TABLE 325. European Union RNA-LNP Formulation Market Size, by Charge, 2017-2032 (USD Million)
  • TABLE 326. European Union RNA-LNP Formulation Market Size, by Anionic, 2017-2032 (USD Million)
  • TABLE 327. European Union RNA-LNP Formulation Market Size, by Cationic, 2017-2032 (USD Million)
  • TABLE 328. European Union RNA-LNP Formulation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 329. European Union RNA-LNP Formulation Market Size, by Gene Editing, 2017-2032 (USD Million)
  • TABLE 330. European Union RNA-LNP Formulation Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 331. European Union RNA-LNP Formulation Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 332. European Union RNA-LNP Formulation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 333. European Union RNA-LNP Formulation Market Size, by Contract Development And Manufacturing Organizations, 2017-2032 (USD Million)
  • TABLE 334. BRICS RNA-LNP Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 335. BRICS RNA-LNP Formulation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 336. BRICS RNA-LNP Formulation Market Size, by miRNA, 2017-2032 (USD Million)
  • TABLE 337. BRICS RNA-LNP Formulation Market Size, by mRNA, 2017-2032 (USD Million)
  • TABLE 338. BRICS RNA-LNP Formulation Market Size, by pDNA, 2017-2032 (USD Million)
  • TABLE 339. BRICS RNA-LNP Formulation Market Size, by siRNA, 2017-2032 (USD Million)
  • TABLE 340. BRICS RNA-LNP Formulation Market Size, by Lipid Composition, 2017-2032 (USD Million)
  • TABLE 341. BRICS RNA-LNP Formulation Market Size, by Cholesterol, 2017-2032 (USD Million)
  • TABLE 342. BRICS RNA-LNP Formulation Market Size, by Ionizable Lipid, 2017-2032 (USD Million)
  • TABLE 343. BRICS RNA-LNP Formulation Market Size, by PEG Lipids, 2017-2032 (USD Million)
  • TABLE 344. BRICS RNA-LNP Formulation Market Size, by Phospholipid, 2017-2032 (USD Million)
  • TABLE 345. BRICS RNA-LNP Formulation Market Size, by Charge, 2017-2032 (USD Million)
  • TABLE 346. BRICS RNA-LNP Formulation Market Size, by Anionic, 2017-2032 (USD Million)
  • TABLE 347. BRICS RNA-LNP Formulation Market Size, by Cationic, 2017-2032 (USD Million)
  • TABLE 348. BRICS RNA-LNP Formulation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 349. BRICS RNA-LNP Formulation Market Size, by Gene Editing, 2017-2032 (USD Million)
  • TABLE 350. BRICS RNA-LNP Formulation Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 351. BRICS RNA-LNP Formulation Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 352. BRICS RNA-LNP Formulation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 353. BRICS RNA-LNP Formulation Market Size, by Contract Development And Manufacturing Organizations, 2017-2032 (USD Million)
  • TABLE 354. G7 RNA-LNP Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 355. G7 RNA-LNP Formulation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 356. G7 RNA-LNP Formulation Market Size, by miRNA, 2017-2032 (USD Million)
  • TABLE 357. G7 RNA-LNP Formulation Market Size, by mRNA, 2017-2032 (USD Million)
  • TABLE 358. G7 RNA-LNP Formulation Market Size, by pDNA, 2017-2032 (USD Million)
  • TABLE 359. G7 RNA-LNP Formulation Market Size, by siRNA, 2017-2032 (USD Million)
  • TABLE 360. G7 RNA-LNP Formulation Market Size, by Lipid Composition, 2017-2032 (USD Million)
  • TABLE 361. G7 RNA-LNP Formulation Market Size, by Cholesterol, 2017-2032 (USD Million)
  • TABLE 362. G7 RNA-LNP Formulation Market Size, by Ionizable Lipid, 2017-2032 (USD Million)
  • TABLE 363. G7 RNA-LNP Formulation Market Size, by PEG Lipids, 2017-2032 (USD Million)
  • TABLE 364. G7 RNA-LNP Formulation Market Size, by Phospholipid, 2017-2032 (USD Million)
  • TABLE 365. G7 RNA-LNP Formulation Market Size, by Charge, 2017-2032 (USD Million)
  • TABLE 366. G7 RNA-LNP Formulation Market Size, by Anionic, 2017-2032 (USD Million)
  • TABLE 367. G7 RNA-LNP Formulation Market Size, by Cationic, 2017-2032 (USD Million)
  • TABLE 368. G7 RNA-LNP Formulation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 369. G7 RNA-LNP Formulation Market Size, by Gene Editing, 2017-2032 (USD Million)
  • TABLE 370. G7 RNA-LNP Formulation Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 371. G7 RNA-LNP Formulation Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 372. G7 RNA-LNP Formulation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 373. G7 RNA-LNP Formulation Market Size, by Contract Development And Manufacturing Organizations, 2017-2032 (USD Million)
  • TABLE 374. NATO RNA-LNP F